作者
Yael Hacohen, Yu Yi Wong, Christian Lechner, Maciej Jurynczyk, Sukhvir Wright, Bahadir Konuskan, Judith Kalser, Anne Lise Poulat, Helene Maurey, Esther Ganelin-Cohen, Evangeline Wassmer, Chery Hemingway, Rob Forsyth, Eva Maria Hennes, M Isabel Leite, Olga Ciccarelli, Banu Anlar, Rogier Hintzen, Romain Marignier, Jacqueline Palace, Matthias Baumann, Kevin Rostásy, Rinze Neuteboom, Kumaran Deiva, Ming Lim
发表日期
2018/4/1
期刊
JAMA neurology
卷号
75
期号
4
页码范围
478-487
出版商
American Medical Association
简介
Importance
Myelin oligodendrocyte glycoprotein antibodies (MOG-Abs) are consistently identified in a range of demyelinating disorders in adults and children. Current therapeutic strategies are largely center specific, and no treatments have been formally evaluated.
Objective
To examine the clinical phenotypes, treatment responses, and outcomes of children with relapsing MOG-Ab–associated disease.
Design, Setting, and Participants
This study prospectively collected demographic, clinical, and radiologic data from 102 patients from 8 countries of the EU Paediatric Demyelinating Disease Consortium from January 1, 2014, through December 31, 2016. Patients were treated according to local protocols.
Main Outcomes and Measures
Annualized relapse rates (ARRs) and Expanded Disability Status Scale (EDSS) scores before and during treatment with disease-modifying drugs (DMDs).
Results
A total of 102 children …
学术搜索中的文章
Y Hacohen, YY Wong, C Lechner, M Jurynczyk… - JAMA neurology, 2018